PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/827,290 TRANSMITTAL Filing Date 4/30/04 **FORM** First Named Inventor Palle et al. Art Unit 1624 **Examiner Name** Berch, Mark L. (to be used for all correspondence after initial filing) Attorney Docket Number 01-0155-CON Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund Express Abandonment Request CD. Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Information Disclosure Statement (2 pages) PTO-SB-08A (1 page) Reply to Missing Parts/ Incomplete Application Search report (4 pages) Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name CV Therapeutics, Inc. Signature Printed name ⊈lin Hartrum

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Marte Bickter

43,663

Date | March 21, 2006

Reg. No.

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

the date shown below:

Typed or printed name

Signature

March 21, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Venkata Palle et al.

Confirmation No.: 2344

Serial No.: 10/827,290

Group Art Unit: 1624

Filing Date: 04/30/2004

Examiner: Berch, Mark L.

Title: A2B adenosine receptor antagonists

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration.

Applicants respectfully request that the Examiner review and make of record the references identified below.

The references identified below were disclosed and/or cited in parent application Serial No. 10/184,494, filed 06/27/2002. As such, copies of the references are not included pursuant to the provisions of 37 CFR § 1.98(d).

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. PATENT DOCUMENTS			
Document No.	Publication Date	Country	
6,770,651	08-03-2004	US	
2003/0149060	08-07-2003	US	

F	OREIGN PATENT DOCUMENTS	
Document No.	Publication Date	Country
01/16134	03-08-2001	WO
00/73307	12-07-2000	WO

NONPATENT DOCUMENTS

As the subject application was filed after June 30, 2003, copies of the U.S. patents and/or publications disclosed in this Information Disclosure Statement are not required and, therefore, are not included.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

Respectfully submitted,

By:

I. Elin Hartrum

Registration No. 43,663

Customer No.: 27716 CV Therapeutics, Inc. 3172 Porter Drive

Palo Alto, California 94304 Telephone: (650) 384-8755 Facsimile: (650) 475-0359 MAR 2 3 2006

Under the Panenunds Reduction Act of 1995, no necesses

PTO-SB-08A (08-00)
Approved for use through 10-31-2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

stitute for form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

pond to a conection of information unless it dis	plays a valid OMB conduit number.
Application Number	10/827,290
Filing Date	04/30/2004
First Named Inventor	Venkata Palle et al.
Group Art Unit	1624 ·
Examiner Name	Berch, Mark L.
Attorney Docket Number	01-0155-CON

U.S. PATENT DOCUMENTS

		U.S. Patent Document				
Examine r Initials	Cite No. ¹		d Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	AA	6,770,651	B2	Palle et al.	08-03-2004	
	AB	2003/0149060	A1	Cristalli et al.	08-07-2003	V)

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document		1	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	Te
Examine r Initials	Cite No. ¹	Office ³	Office ³ Number ⁴ KindCode ⁵					
	AW	wo	01/16134	A1	Vanderbilt University	03-08-2001		
	AX	wo	00/73307	A2	University of Virginia	12-07-2000		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.